Inactivation of the switch/sucrose nonfermentable complex component SMARCB1 is extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors. This alteration is hypothesized to confer oncogenic dependency on EZH2 in these cancers. We report the discovery of a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activ-
Inactivation of the switch/sucrose nonfermentable complex component SMARCB1 is extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors. This alteration is hypothesized to confer oncogenic dependency on EZH2 in these cancers. We report the discovery of a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity, (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide). The compound induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells. Treatment of xenograft-bearing mice with (N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide) leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and portend the utility of EZH2-targeted drugs for the treatment of these genetically defined cancers.
epigenetic cancer therapy | EZH2 inhibitor P osttranslational modifications of core histone proteins of chromatin play important roles in controlling the fidelity of gene transcription patterns in cells (1) . Paramount among these transcription-controlling modifications is methylation events at lysine and arginine residues, catalyzed by histone methyltransferases (HMTs) (2) . EZH2 is the catalytic subunit of the multiprotein HMT complex known as polycomb repressive complex 2 (PRC2), catalyzing the methylation of lysine 27 of histone H3 (H3K27); trimethylation of H3K27 leads to repression of gene expression (3) . EZH2 has been implicated in several cancer types by mutation, amplification, and/or overexpression (4) . For instance, heterozygous EZH2 mutations at residues within the catalytic (Su[var]3-9, enhancer of zeste, trithorax) (SET) domain have been observed in 10% of non-Hodgkin lymphomas and can drive H3K27 hypertrimethylation, abnormal gene expression, and lymphomagenesis. We and others previously reported that selective inhibition of EZH2 results in selective killing of lymphoma cells bearing EZH2 mutations, suggesting that EZH2 enzymatic activity is a required driver of proliferation in the mutant-bearing cells (5) (6) (7) .
Gene expression is also regulated by remodeling of nucleosomes in an ATP-dependent manner (8) . Of the ATP-dependent chromatin remodelers, switch/sucrose nonfermentable (SWI/ SNF) complexes are emerging as bona fide tumor suppressors, as specific inactivating mutations in several SWI/SNF subunits are found in human cancers (9) . For instance, the SMARCB1 subunit (also known as SNF5, INI1, or BAF47) is inactivated via biallelic mutations in nearly all malignant rhabdoid tumors (MRTs) and atypical teratoid rhabdoid tumors (ATRTs), aggressive cancers of young children with no effective therapy (10). Gene expression and functional studies in cell culture demonstrated that SMARCB1 loss leads to decreased expression of cell cycle inhibitors (11), tumor suppressors like BIN1 (12), and genes of neuronal differentiation (13, 14) , while hedgehog and MYC pathway genes were up-regulated (14, 15) . Homozygous SMARCB1 knockout mice are embryonically lethal, but SMARCB1-heterozygous mice are viable and develop sarcomas that closely resemble human MRTs with the second allele of SMARCB1 spontaneously lost (16) . SMARCB1-conditional inactivation in T cells leads to fully penetrant T-cell lymphomas at a median age of onset of 11 wk (17) . Interestingly, tumorigenesis can be completely suppressed by tissue-specific codeletion of EZH2, suggesting an antagonistic interaction between PRC2 and SWI/SNF. Indeed, EZH2 expression is elevated in primary SMARCB1-deficient tumors, and polycomb target genes are also broadly repressed in such tumors as well as in SMARCB1 knockout mouse embryonic fibroblasts.
Through iterative medicinal chemistry, we have developed a selective EZH2 inhibitor with favorable pharmacological properties. The compound was used to test whether SMARCB1-deleted MRTs are selectively sensitive to EZH2 inhibition in vitro and in vivo, which would suggest new treatment modalities for such genetically defined cancer types.
Results

EPZ-6438
Is a Potent and Selective Inhibitor of EZH2. High-throughput screening afforded a pyridone-containing EZH2 inhibitor series (5), and through iterative medicinal chemistry, we developed (Fig. 1A) , a compound with superior potency and pharmacokinetic properties relative to our previously described tool compound 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(morpholinomethyl) phenyl)-1H-indazole-4-carboxamide (5) (EPZ005687). EPZ-6438 inhibited the activity of human PRC2-containing wild-type EZH2 with an inhibition constant (K i ) value of 2.5 ± 0.5 nM, and similar potency was observed for EZH2 proteins bearing all known Author contributions: S.K.K., R.C., M.P.M., V.M.R., K.W.K., and H.K. designed research; S.K.K., N.M.W., T.J.W., and H.K. performed research; C.R.K., C.J.A., A.R., and K.W.K. contributed new reagents/analytic tools; S.K.K., N.M.W., T.J.W., M.P.S., R.C., M.P.M., R.A.C., V.M.R., R.M.P., K.W.K., and H.K. analyzed data; and S.K.K., R.A.C., R.M.P., and H.K. wrote the paper. lymphoma change-of-function mutations (Table S1). As previously described for EPZ005687 (5) , steady-state analysis of the enzyme kinetics revealed that the present compound, EPZ-6438, inhibits EZH2 in a manner competitive with the substrate S-adenosylmethionine (SAM) (that is, EPZ-6438 and SAM binding to EZH2 is mutually exclusive, such that only one or the other ligand can bind but both cannot bind to the enzyme simultaneously) (Fig. S1A ), and noncompetitive with the peptide or nucleosome substrate (that is, EPZ-6438 binding is not mutually exclusive or synergistic with binding of the peptide/nucleosome substrate of the enzymatic reactions) (Fig. S1B) (18) . We also assessed inhibition by EPZ-6438 against a panel of HMTs other than EZH2 encompassing both lysine and arginine HMTs. EPZ-6438 displayed a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs tested (Table S1 ). These in vitro properties (i.e., mechanism of action, specificity, cellular potency) of EPZ-6438 (Table S2) . are similar to those of other published EZH2 inhibitors (6, 7 Table S2 ). Treatment of either wild-type or mutant cells resulted in diminution of H3K27 methylation, whereas other histone methyl marks were unaffected (Fig. S2B) . In vitro treatment of SMARCB1-deleted MRT cell lines with EPZ-6438 induced strong antiproliferative effects with IC 50 values in the nanomolar range, whereas the control (wild-type) cell lines were minimally affected ( Fig. 1 C and D and Table S2 ). Antiproliferative effects were apparent in SMARCB1-deleted MRT cells after 7 d of compound exposure, but required 14 d of exposure for maximal activity. We also assessed the effects of incubation with EPZ-6438 (1 μM) for 14 d on cell cycle progression and apoptosis in G401 and RD cells. EPZ-6438 incubation of RD (SMARCB1 wild-type) cells showed no changes in cell cycle or apoptosis compared with the DMSO control ( Fig. 2A) . In contrast, G401 (SMARCB1-deleted) cells showed an increase in the percentage of cells in G 1 phase, and a concomitant decrease in S phase and G 2 /M phase after 7 d (Fig. 2B) . There was no apparent increase in the sub-G 1 fraction through day 7, suggesting that apoptosis was not yet induced by that time. This coincides with the growth curves of G401 cells in the presence of EPZ-6438 that display cytotoxicity only after 7 d of incubation (Fig. 1C) . Following EPZ-6438 treatment of G401 cells for up to 14 d, the fraction of cells in sub-G 1 as well as apoptotic cells determined by TUNEL assay increased in a time-dependent manner through days 11 and 14, indicating that EPZ-6438-mediated cell death occurred through the induction of apoptosis (Fig. 2B) .
EPZ-6438 Induces Genes of Neuronal Differentiation and Cell Cycle Inhibition While Suppressing Expression of Hedgehog Pathway Genes, MYC and EZH2. It has been suggested that SMARCB1 loss drives cancer formation through simultaneous epigenetic perturbation of key cancer pathways (19) . We confirmed the previously described reduced expression of genes important for neuronal differentiation (CD133, DOCK4, PTPRK), cell cycle inhibition (CDKN2A), and tumor suppression (BIN1), as well as increased expression of the hedgehog pathway gene GLI1 in SMARCB1-deleted G401 cells compared with control cells (Fig. 3A) . CDKN1A and CDKN2A and tumor suppressor BIN1, all in a time-dependent manner (Fig. 3B) . At least one of these genes (CDKN2A) is known to be a direct target of PRC2 repression (17) . EPZ-6438 also down-regulated the expression of hedgehog pathway genes MYC and EZH2 over the same time period. Concomitant with these transcriptional changes, we additionally observed morphological changes in another SMARCB1-deleted cell line, G402. When exposed to EPZ-6438 for 14 d, the G402 cells (but not the G401 cells) assumed a neuron-like morphology (Fig.  3C and Fig. S3 ). In contrast, EPZ-6438 incubation of RD control cells had minimal effects on expression of the above-mentioned genes or on cell morphology.
EPZ-6438 Leads to Complete and Sustained Regression of SMARCB1
Mutant MRT Xenografts. A study in SCID mice bearing s.c. G401 xenografts was performed where animals were dosed orally for 21 d with EPZ-6438. One-half of the mice per group were euthanized on day 21 to collect blood and tissues, while the remaining animals were treated for an additional 7 d and then left without dosing for another 32 d. EPZ-6438 was well tolerated at all doses with minimal effect on body weight (Fig. S4A) . Oral dosing at 250 or 500 mg/kg twice daily (BID) for 21-28 d practically eliminated the fastgrowing G401 tumors (Fig. S4 B and C and Fig. 4A ). Regrowth was not observed for 32 d after dose cessation. EPZ-6438 dosed at 125 mg/kg induced tumor stasis during the administration period and produced a significant tumor growth delay compared with vehicle after the dosing period. Measuring EPZ-6438 plasma levels either 5 min before or 3 h after dosing on day 21 revealed a clear dosedependent increase in systemic exposure (Fig. S4D) . Tumors that were harvested from subsets of mice from each group on day 21 showed strong inhibition of H3K27Me3, correlating with the antitumor activity (maximum effect achieved at 250 mg/kg; . 4B ). In addition, dose-dependent changes in the expression of CD133, PTPRK, DOCK4, and GLI1 were detected in the G401 xenograft tumors (Fig. 4C) .
Discussion
MRTs and ATRTs are extremely aggressive pediatric cancers of the brain, kidney, and soft tissues that are highly malignant, locally invasive, frequently metastatic, and particularly lethal (10) . They are typically diploid and lack genomic aberrations; however, they are characterized by an almost complete penetrance of loss of SMARCB1, a core component of the SWI/SNF chromatin remodeling complex (20) . The biallelic inactivation of SMARCB1 is in essence the sole genetic event in MRTs and ATRTs, which suggests a driver role for this genetic aberration. Through genetic studies, it has been suggested that PRC2 and SWI/SNF antagonistically regulate gene expression around several pathways including RB, Cyclin D1, MYC (19) , and hedgehog (15) . Analyses of rhabdoid tumor tissue and functional studies suggest that such cancers may originate from early stem cells where chromatin around specific genes remains dominated by PRC2 histone markings (14) . At the time of differentiation, absence of SMARCB1 in rhabdoid tumors prevents the de-repression of such genes (which would normally occur in the SMARCB1 wild-type setting), leading to aberrant activation of proliferation, survival, and self-renewal pathways and oncogenesis. These results provide a successful testing of the hypothesis that pharmacological inhibition of EZH2 enzymatic activity would provide a basis for therapeutic intervention in MRTs and ATRTs. In the present report, we show that pharmacological inhibition of EZH2 induced antiproliferative effects specifically in SMARCB1-deleted MRT cell lines and led to complete regressions of MRT xenografts in mice without any regrowth for the full duration of the study. These data confirm the dependency of such cancers on PRC2 activity, despite the fact that EZH2 itself is not genetically altered in this context. Our results in MRT cell culture are similar to findings by Alimova et al. (21) showing that disruption of EZH2 by RNAi and/or 3-Deazaneplanocin A (DZNep, an indirect and general inhibitor of methyltransferases) impairs ATRT cell growth. Interpretation of cellular phenotypes caused by DZNep, however, is complicated by its ability to reduce methylation levels at multiple histone residues targeted by HMTs other than EZH2.
Numerous studies show that reconstitution of SMARCB1 into MRT or ATRT cells restores the abnormal gene expression pattern (for instance by increasing expression of cell cycle inhibitors and tumor suppressors) and leads to impaired cell growth (22) . Here, we show that, in the context of SMARCB1-deleted MRT, inhibition of EZH2 functions as a SMARCB1 surrogate and derepresses neuronal differentiation genes, cell cycle inhibitors, and tumor suppressors while reducing GLI1, PTCH1, MYC, and EZH2. The sum of the effects of EPZ-6438-mediated EZH2 inhibition on several cancer pathways is likely the cause for the dramatic and permanent antitumor activity seen in MRT models. This suggests that EPZ-6438 may represent a new and exciting potential treatment modality for these lethal childhood tumors. Furthermore, because several members of the SWI/SNF complex are genetically altered in other cancer types besides MRT, it is conceivable that EZH2 may also play a role in tumor maintenance and survival in a spectrum of cancer types. Combined with recent reports demonstrating the effectiveness of EZH2 inhibitors in selective killing of EZH2 mutant bearing non-Hodgkin lymphomas, the present data suggest that small-molecule-based inhibition of EZH2 may be an effective mechanism of therapeutic intervention in a variety of hematologic and solid tumors for which genetic alterations-either target-directed or indirect-confer a proliferative dependency on EZH2 enzymatic activity.
Materials and Methods
Synthesis of EPZ-6438. A synthetic route of EPZ-6438 is described in patent cooperation treaty (PCT) patent application publication number WO/2012/142504. Biochemical Methods. Methods to assay HMT activities were performed as previously described (5). Western Blots Analysis. Histones were acid extracted as previously described (23) . Western blots for acid-extracted histones were performed as previously described (5) . Western blot conditions for whole-cell lysates are described in SI Text.
In Vitro Cell Assays. For the adherent cell line proliferation assays [all cell lines except KYM-1, which was analyzed as previously described for suspension cell lines (22) ], plating densities for each cell line were determined based on growth curves (measured by ATP content) and density over a 7-d time course. On the day before compound treatment, cells were plated in either 96-well plates in triplicate (for the day 0-7 time course) or 6-well plates (for replating on day 7 for the remainder of the time course). On day 0, cells were either untreated, DMSO-treated, or treated with EPZ-6438 starting at 10 μM and decreasing in either threefold or fourfold dilutions. Plates were read on day 0, day 4, and day 7 using Cell Titer Glo (Promega), with compound/media being replenished on day 4. On day 7, the six-well plates were trypsinized, centrifuged, and resuspended in fresh media for counting by Vi-Cell. Cells from each treatment were replated at the original density in 96-well plates in triplicate. Cells were allowed to adhere to the plate overnight, and cells were treated as on day 0. On days 7, 11, and 14, plates were read using Cell Titer Glo, with compound/media being replenished on day 11. Averages of triplicates were used to plot proliferation over the time course, and calculate IC 50 values. For cell cycle and apoptosis, G401 and RD cells were plated in 15-cm dishes in duplicate at a density of 1 × 10 6 cells per plate. Cells were incubated with EPZ-6438 at 1 μM, in a total of 25 mL, over a course of 14 d, with cells being split back to original plating density on day 4, 7, and 11. Cell cycle analysis and TUNEL assay were performed using a Guava flow cytometer, following the manufacturer's protocol. . Gene expression was normalized to 18S (AB; Hs99999901_s1), and fold change was calculated using the ΔΔCt method. For the in vivo samples, the average Ct value ± SD was determined for each dose group and fold change compared with vehicle dose group was calculated using the ΔΔCt method.
Measurement of H3K27 Methylation in Tumor Tissue. Histones were isolated from tumors as previously described (23) and were prepared in coating buffer (PBS with 0.05% BSA). Two independent ELISAs were performed using antibodies specific for H3K27Me3 (CST; 9733) or total H3 (Abcam; ab1791), and ratios for H3K27Me3 to total H3 were calculated. The detailed procedure is described in SI Text. The treatments were started when the tumor size reached ∼157 mm 3 for the tumor efficacy study (n = 16 mice per group). EPZ-6438 or vehicle (0.5% NaCMC plus 0.1% Tween 80 in water) was administered orally BID at a dose volume of 10 μL/g for either 21 or 28 d. Animal body weights were measured every day during the first week, and then twice weekly for the remainder of the study. Tumor size was measured twice weekly in two dimensions using a caliper, and the volume was expressed in cubic millimeters. For pharmacokinetic-pharmacodynamic analysis, eight mice with the largest tumor burden were euthanized for tumor and blood collection after 21 d of dosing. The remaining mice continued dosing for 1 more week, and from day 29, treatment was stopped and the mice were enrolled in a tumor growth delay study. Mice were observed as individuals until they reached the tumor weight endpoint (2,000 mm 3 ) or until day 60 (whichever came first).
